In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

That Ozempic (or Wegovy, the name by which the weight-loss version of the drug semaglutide is marketed) should have proliferated in an industry that has always venerated thinness will hardly come as a ...

The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...

Semaglutide belongs to a class of prescription medications that mimic a hormone your body naturally produces after you eat. This hormone helps your pancreas make insulin, which lowers your blood sugar ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

On Tuesday, U.S. Senator Mike Braun (R-Ind.) questioned Novo Nordisk CEO Lars Fruergaard Jørgensen at the Senate Health, ...

The injection has previously been used to treat diabetes , but has faced criticism in recent months after a string of celebs ...

In 1970, with a degree from the medical school of the University of Copenhagen (UCPH), Professor Jens Juul Holst embarked on ...

James Corden revealed that he gave Ozempic a try to help with weight loss, but soon found that his relationship with food had little to do with how hungry he was or wasn't.

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

With 890 million people affected globally and 42% of American adults classified as obese, the allure of a "miracle" weight ...